GenSight Biologics SA (SIGHT) AI Stock Analysis

• Market Cap: €24.44M
• Dividend Yield: N/A
• Average Volume (3M): 481.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: -50.00%
• EPS Growth: 73.05%
• Country: FR
• Employees: 16
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 154,726,440
• 10 Day Avg. Volume: 187,454
• 30 Day Avg. Volume: 481,055
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.40
• Price Target Upside: 150.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 47 Neutral
• Price Target: €0.00 ▼(-100.00% Downside)

The overall stock score is primarily impacted by the company's challenging financial position, characterized by persistent losses and high leverage. Technical analysis provides some neutral signals, but valuation concerns due to negative earnings further weigh down the score.

GenSight Biologics SA Business Overview & Revenue Model

Company Description

GenSight Biologics SA is a biotechnology company focused on developing innovative gene therapies to treat severe retinal diseases and neurodegenerative disorders. The company specializes in harnessing its proprietary gene therapy platform to create targeted treatments aimed at restoring vision and improving the quality of life for patients with genetic conditions affecting the retina. Its core products include gene therapies that are currently in various stages of clinical trials, with an emphasis on conditions such as Leber Hereditary Optic Neuropathy (LHON) and other inherited retinal diseases.

How the Company Makes Money

GenSight Biologics generates revenue primarily through the commercialization of its gene therapy products once they receive regulatory approvals. The company also benefits from strategic partnerships and collaborations with larger pharmaceutical companies, which may involve milestone payments, research funding, and profit-sharing agreements. Additionally, grants and funding from governmental and non-governmental organizations dedicated to advancing innovative medical treatments contribute to the company's financial resources. These revenue streams are crucial for supporting ongoing research and development efforts as well as clinical trials aimed at bringing new therapies to market.

GenSight Biologics SA Financial Statement Overview

Summary

GenSight Biologics SA is experiencing significant financial challenges, with persistent losses, negative stockholders' equity, and heavy reliance on debt. Despite some revenue growth, the company's financial health remains precarious, heavily dependent on external financing.

Income Statement

GenSight Biologics SA has experienced inconsistent revenue trends over the years, with a notable revenue decline in 2021 and subsequent volatility. The gross profit margin is consistently high, but the company faces significant challenges in profitability, as evidenced by consistently negative net income and EBIT margins. The recent year shows improvement in revenue but still struggles with substantial losses, indicating ongoing financial challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is unfavorable due to negative equity, and return on equity is not meaningful under these circumstances. The equity ratio is also negative, highlighting a risky financial position with heavy reliance on debt.

Cash Flow

The cash flow statement indicates negative operating cash flow, but there has been improvement in free cash flow growth in recent years. However, the free cash flow to net income ratio is negative, reflecting ongoing operational challenges. The company relies heavily on financing activities to support its cash flow needs.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.63M	1.27M	2.58M	5.28M	4.39M
Gross Profit	2.63M	3.00M	2.58M	5.28M	4.39M
EBITDA	-14.76M	-21.73M	-26.44M	-26.83M	-34.13M
Net Income	-14.00M	-26.22M	-27.62M	-28.62M	-34.02M
Balance Sheet
Total Assets	10.76M	9.13M	25.94M	56.65M	47.36M
Cash, Cash Equivalents and Short-Term Investments	2.46M	2.13M	10.61M	44.29M	37.94M
Total Debt	19.11M	18.43M	12.65M	12.57M	14.45M
Total Liabilities	37.68M	39.83M	41.22M	40.66M	35.69M
Stockholders Equity	-26.92M	-30.67M	-15.28M	15.99M	11.67M
Cash Flow
Free Cash Flow	-12.94M	-24.67M	-34.01M	-17.17M	-15.05M
Operating Cash Flow	-12.94M	-24.66M	-33.75M	-17.14M	-15.04M
Investing Cash Flow	17.00K	209.00K	172.00K	-16.00K	-376.00K
Financing Cash Flow	13.54M	15.86M	95.00K	23.74M	33.86M

GenSight Biologics SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.16
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:SIGHT, the sentiment is Negative. The current price of 0.16 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.15, and below the 200-day MA of 0.23, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.83 is Neutral, neither overbought nor oversold. The STOCH value of 21.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:SIGHT.

GenSight Biologics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.90B	-0.33	-41.70%	2.23%	23.45%	-1.99%
SIGHT	47 Neutral	€24.44M	―		―	-50.00%	73.05%
0RCQ	―	€23.64M	―		―	―	―
0RA2	―	€16.38M	―		―	―	―
3MM	―	€17.96M	―		―	―	―
8JD	―	€19.64M	―		―	―	―
82F	―	€18.22M	―	-313.76%	―	―	―